*smith&nephew Getting Management Buy-In Soft Sell Tie compliance to “Core Values” “Corporate Mantra” Competitive differentiation: Sell relationship safety.

Slides:



Advertisements
Similar presentations
Our Goals Today To help you feel comfortable with asking questions.
Advertisements

Chapter 6 Federal Regulation of Pharmacy Practice.
© 2009 Cengage Learning. All Rights Reserved. Healthcare Fraud and Abuse.
HUD & OIG.
John W. McReynolds Assistant Chief, New York Field Office Antitrust Division, U.S. Department of Justice Judicial Training Program Moscow, Russia July.
Sales & Marketing Compliance Training
Medicare Parts C and D Fraud, Waste, and Abuse Compliance Training
The United States False Claims Act Qui Tam Whistleblower Law Getnick & Getnick LLP | Counsellors At Law Rockefeller Center, 620 Fifth Avenue | New York,
What Can YOU Do to Help Prevent Healthcare Fraud? Sponsored by: Idaho Commission on Aging Senior Medicare Patrol Program Presented by: (Presenter name,
Regulatory Control of Providers Financial Relationships Civil False Claims The Act.
AAA-PRACTICE COMPLIANCE COMMITTEE PRESENTS: ANTIKICKBACK STATUTE & STARK LAWS AS THEY APPLY TO AUDIOLOGY PRACTICES.
What Can YOU Do to Prevent Healthcare Fraud? Funded by: This project is supported in part by grant numbers 90MP0026 and 90MP0127 from the U.S. Administration.
Affordable Care Act & Older Adults Presented By: Kristen Benevides, Sherry Tanaka, Malloree Ullrich, & Abraleen Keliinui.
Healthcare Fraud David Burris Senior Director Alvarez & Marsal Dispute Analysis & Forensic Services Washington DC/Tampa FL 21st Annual ECI Conference.
How to Make $4.1Billion in 12 Months: Healthcare Fraud and Abuse Enforcement Mark Bartlett Davis Wright Tremaine, LLP.
# Operating Under the New Compliance Environment: Considerations for the Pharmaceutical Industry The Impact of the new Medicare Prescription Drug benefit.
1 Medicaid Fraud and Abuse Investigations, Prosecutions and Compliance Strategies John T. Bentivoglio Combating Medicaid.
STATE OF LOUISIANA DEPARTMENT OF JUSTICE CRIMINAL DIVISION MEDICAID FRAUD CONTROL UNIT Post Office Box Baton Rouge, Louisiana Telephone:
© 2009 The McGraw-Hill Companies, Inc. All rights reserved. 1 McGraw-Hill Chapter 5 HIPAA Enforcement HIPAA for Allied Health Careers.
Copyright © 2008 Delmar Learning. All rights reserved. Chapter 5 Legal and Regulatory Issues.
Medicare Advantage & Part D Compliance Training 2009.
Copyright© 2011 WeComply, Inc. All rights reserved. 9/6/2015 Whistleblowing.
Copyright © 2005 Thomson Delmar Learning. ALL RIGHTS RESERVED.1 This product was funded by a grant awarded under the President’s Community-Based Job Training.
Voluntary Codes MassMEDIC Meeting Are You Ready to Comply with Massachusetts’ New Pharmaceutical and Medical Device Code of Conduct Law? Linda D. Bentley,
Blue Cross of Idaho Medicare Advantage Provider Fraud, Waste and Abuse Training Fall 2009.
Copyright ©2011 by Pearson Education, Inc. Upper Saddle River, New Jersey All rights reserved. Pearson's Comprehensive Medical Assisting: Administrative.
Fraud and Abuse in Dentistry. Definition Fraud is the intentional perversion of truth in order to induce another to part with something of value, or surrender.
RISK MANAGEMENT IN THE TREATMENT OF OPIOID DEPENDENCE Presented by: Barbara A. M. Maloney, Esq.
1 VIEW ON FRAUD AND ABUSE David E. Matyas Epstein Becker & Green Washington, DC.
+ Conflict of Interest in Physician-Industry Relationships.
U.S. Environmental Protection Agency Office of Criminal Enforcement, Forensics, & Training Jeffrey Denny, Resident Agent in Charge Indianapolis Resident.
Healthcare Compliance: 2014 Stuart Freedman, MPH HSC Chief Compliance Officer Monica Wilson, JD, CHC Manager, HSC Compliance.
KEY ENFORCEMENT ISSUES - The Government's Perspective Kathleen Meriwether Assistant United States Attorney Eastern District of Pennsylvania UNITED STATES.
Chapter 14 Financing. Copyright © 2005 by Thomson Delmar Learning. ALL RIGHTS RESERVED.2 Personal Health Care Expenditures, 1965 Physicians 20% Nursing.
The Ninth Annual Pharmaceutical Regulatory Compliance Congress and Best Practices Forum Thomas E. Costa Bristol-Myers Squibb Company This presentation.
Enforcing IP Rights Involving Foreign Companies Greg Vogler Chicago, Illinois May 2013.
1 National Pharma Audioconference: Pharmaceutical Drug Pricing and Reporting Issues Overview of Department of Justice Prosecution of Drug Pricing and Reporting.
When Pharmaceutical Marketing Crosses the Line: Best Practices For Investigation and Remediation.
1 Continuing Medical Education and Industry Sponsorship The Pharma, Biotech and Device Colloquium Princeton, NJ June 7, 2005 Julie K. Taitsman, M.D., J.D.
THE SECOND ANNUAL FDA REGULATORY AND COMPLIANCE SYMPOSIUM THOMAS M. GREENE Greene & Hoffman August 25, 2006 LESSONS FROM WHISTLE-BLOWER CASES.
National Medical Device Audioconference: How the Recent Landmark $311 Million Device Settlements Will Change Industry Practices Insights Into Federal Investigations.
Welcome General Compliance Training.  To inform you who to contact to ask questions  To let you know that you are responsible to disclose  To share.
1 Pharmacy Management and Cost-Containment: Pharmaceutical Fraud Investigations, Prosecutions and Compliance Strategies John T. Bentivoglio
Enforcement Trends in the Pharmaceutical Industry Lewis Morris Chief Counsel Office of Inspector General, DHHS.
MmPHR Use Cases Oxyconton Fraud Business Model Rubina Lakhani March 2, 2016.
Lessons Learned from Federal Prosecutions Michael K. Loucks First Assistant U.S. Attorney District of Massachusetts.
The Growing Role of HHS-IG/DOJ, & Whistleblowers, In Drug Marketing Policy John F. Kamp August 25, 2005.
Chapter 4 The Legal and Regulatory Environment of Health Care.
© 2016 McGraw-Hill Education. All rights reserved. Ch 8 Privacy, Security and Fraud.
Why 30-Day Pharmacy Payment Cycles Lower Costs and Prevent Fraud
Strike Force Operations SA Jeff Richards
Us Healthcare System.
Compliance and Enforcement Roundtable Discussion
Action Items: Monitoring Off-Label Promotion Do’s and Don’t’s
RISK MANAGEMENT IN THE TREATMENT OF OPIOID DEPENDENCE
FRAUD, WASTE, & ABUSE (FWA) 2012
PHARMA AUDIOCONFERENCE An Analysis of the HHS OIG Draft Compliance Program Guidance for the Pharmaceutical Industry Overview of Draft CPG Michael P.
DOJ Pharmaceutical Prosecutions
Northern Michigan Regional Entity Region 2
11/27/2018 The First International Medical Device Compliance Congress May 27, Paris, France Track 3.01 Managing Investigations and Compliance Programs.
OIG Enforcement Initiatives
Seven Ways To Protect Your Company
CMS CENTERS FOR MEDICARE AND MEDICAID SERVICES
National Medicaid Congress
Health Care Fraud Investigations
Brussels, June 6, 2007 Paul E. Kalb, M.D., J.D.
Compliance, Ethics, and Audit
2006 PHARMACEUTICAL REGULATORY AND COMPLIANCE CONGRESS NOVEMBER 9,2006
SUBROGATION AND THE OPIOID EPIDEMIC
Fraud, Waste & Abuse (FWA) Education Related to Sales Activities
Presentation transcript:

*smith&nephew Getting Management Buy-In Soft Sell Tie compliance to “Core Values” “Corporate Mantra” Competitive differentiation: Sell relationship safety to employees and customers (e.g., insurance: the “good hands people” theme) Rational Sell Give them numbers: Dollars and Sense Issues for Govt. Cost Avoidance: share price, investigations and outside lawyers, damage to brand, recruiting and retention Scare Sell Government warnings for device makers: Quote the DOJ and OIG Cases and consequences for companies: chance of exclusion Cases against sales execs and officers: Serono and TAP execs Steroids Analogy: competitive edge, get caught, get banned

*smith&nephew Rational Sell: Govt. Health Spending Soaring YearAll Healthcare Expenditures Percentage of US GDP MedicareMedicaid (Poor) Total Federal ** ** , , Medicare Part D +$500,000,000,000+

*smith&nephew Scare Sell: Healthcare Enforcement Statistics Billion in criminal and civil fines Civil sanctions against doctors from $20,000 to $611, criminal defendants charged, 437 convicted 96-03: criminal cases up 47% per year

*smith&nephew Scare Sell: Learning Compliance the Hard Way Pfizer– Guilty Plea and Settlement – $420 million (May 2004) TAP Pharmaceuticals – Settlement – $875 million (2001) Schering-Plough – Settlement – $345 Million Abbot Laboratories – Settlement – $614 Million

*smith&nephew Really Scary Sell: Serano Labs – Adam Stupak (According to press reports citing indictment) Serano sold Serostim, AIDs wasting drug: 12 week courses at $21, % cases covered by Medicaid funded programs Allegation: VPs of Marketing and Sales call six RSDs to Boston to “dig their way out” of a shortfall in company’s sales goal. Launched “$6m-6 Day Plan” – offering key physicians deemed “thought leaders” free trips with guest to healthcare conference in Cannes, France, if they agreed to Rx Serostim. RSDs executed: Some doctors rejected, but 10 accepted, wrote Rx, took trip with guest. Serano paid “thousands” for the trips, and announced the 10 doctors in a press statement. Doctors referred to in the indictment only by their initials.

*smith&nephew Really Scary Sell: Don’t be a Stupak Adam Stupak–Regional Sales Director – Guilty Plea on ; Sentencing Spring 05 5 years federal prison 3 years post-release supervision $25,000 fine per count Criminal fines not dischargeable in bankruptcy What about Company? Execs? Other RSDs? Doctors? 11 TAP execs on trial Spring 2004

*smith&nephew Really Scary Sell: More Serano Labs Headline April 15, 2005 execs charged with luring physicians with trips Indicted: John Bruens, 48, VP of Marketing, 7 counts Indicted: Mary Stewart, 44, VP of Sales, 7 counts Indicted: Melissa Vaughn, 43, Regional Sales Director, 2 counts Indicted: Marc Sirockman, 41, Regional Sales Director, 2 counts Charges: consipracy to violate the Anti-Kickback Statute Jeopardy: 5 years prison; up to $250,000 fine per count April 23, 2005: Serono reserves $725 Million for possible settlement

*smith&nephew Government Target: Device Industry “The detection and elimination of health care fraud and abuse is a top priority of Federal law enforcement” United States Department of Health and Human Services and the Department of Justice Health Care Fraud and Abuse Control Program Annual Report for FY 2001 The Department of Health and Human Services plans to accelerate its investigations of alleged fraud and abuse by medical device companies... The inquiries will likely center on kickbacks and other improper sales and marketing deals between doctors and companies in the fast-growing industry.... Executives in the medical device industry can expect even more actions within a year to 18 months as the workload from pharmaceutical investigations winds down.... Cases against other device makers are going to be coming into the pipeline.... The medical device salespeople are engaged in the same fraud [as the Pharmaceutical companies]. Recent comments of Lewis Morris, Chief Counsel to the Health and Human Service’s Department of the Inspector General: